Literature DB >> 16393517

Evaluation of P-POSSUM scoring system in predicting mortality in patients with hip joint arthroplasty.

Gui-shan Gu1, De-bao Zhang, Bo-hao Zhang, Nai-kun Sun.   

Abstract

OBJECTIVE: To evaluate the applicability of Porthsmouth modified physiological and operative severity score for the enumeration of mortality and morbidity (P-POSSUM) in predicting the mortality of the patients undergoing hip joint arthroplasty.
METHODS: A total of 141 patients (75 males and 66 females, aged 63.22 years+/-14.45 years on an average) undergoing hip joint arthroplasty during January 2002 and March 2005 were studied retrospectively with P-POSSUM. Their average physiological score and operative severity score were 17.48+/-5.16 and 12.43+/-3.05, respectively. The predicted postoperative mortality with P-POSSUM was compared with the observed value. Subgroup analysis was performed to investigate the predictive capability of P-POSSUM. POSSUM scoring system was used as the control.
RESULTS: Three patients died after operation in this study actually. The average physiological scores were 32.33+/-9.87 in the death group and 17.16+/-4.56 in the survival group. The former was obviously higher than the latter, which showed statistical difference between the two groups (Wilcoxon rank sum test, P<0.05). Perfect agreement was found between the observed death number and the predicted death number calculated by P-POSSUM (Cochran-Mantel-Haenszel chi(2) test, P>0.05), though POSSUM overestimated the overall mortality.
CONCLUSIONS: P-POSSUM can predict the mortality accurately in the patients undergoing hip joint arthroplasty, which is superior to POSSUM.

Entities:  

Mesh:

Year:  2006        PMID: 16393517

Source DB:  PubMed          Journal:  Chin J Traumatol        ISSN: 1008-1275


  1 in total

1.  Good overall morbidity prediction with the POSSUM scoring system in patients having a total hip or knee replacement - a prospective study in 227 patients.

Authors:  Mattias Hildén; Per Wretenberg; Wilhelmina Ekström
Journal:  Clin Interv Aging       Date:  2018-09-13       Impact factor: 4.458

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.